Across TCGA pan-cancer cohorts, RTEL1-TNFRSF6B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RTEL1-TNFRSF6B data layer compared with 23 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RTEL1-TNFRSF6B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RTEL1-TNFRSF6B expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
LSCC, HNSC, and LUAD are the cancer types where RTEL1-TNFRSF6B mass-spec protein most reproducibly stratifies survival.